



Clinical trial results:

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria

Summary

EudraCT number	2007-003458-28
Trial protocol	Outside EU/EEA
Global end of trial date	17 September 2008

Results information

Result version number	v1 (current)
This version publication date	30 June 2016
First version publication date	18 June 2015

Trial information

Trial identification

Sponsor protocol code	A00423
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00628108
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	UCB, Inc.
Sponsor organisation address	1950 Lake Park Drive, Smyrna, United States, 30080
Public contact	Clinical Trial Registries and Results Disclosure, UCB BIOSCIENCES GmbH, 0049 2173 48 15 15, clinicaltrials@ucb.com
Scientific contact	Clinical Trial Registries and Results Disclosure, UCB BIOSCIENCES GmbH, 0049 2173 48 15 15, clinicaltrials@ucb.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 October 2008
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	17 September 2008
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to evaluate the safety of levocetirizine dihydrochloride (LCTZ) in pediatric subjects aged from 6 to 11 months.

Protection of trial subjects:

Adequate information was provided to the subject's caregiver in both oral and written form and consent was obtained in writing prior to performance of any study specific procedure. The content and process of obtaining informed consent was in accordance with all applicable regulatory and IEC/IRB requirements.

Background therapy:

N/A

Evidence for comparator:

N/A

Actual start date of recruitment	20 March 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 69
Worldwide total number of subjects	69
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	69
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

The A00423 study began enrollment in March 2008. The study concluded in September 2008 with 69 subjects enrolled.

Pre-assignment

Screening details:

One subject was randomized to levocetirizine but received placebo; hence the number of subjects in both treatment groups in the Safety Population differs by 1 from the number of the subjects randomized (STARTED) to the respective treatment group.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Carer, Subject

Blinding implementation details:

N/A

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Placebo
------------------	---------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	PBO
Other name	
Pharmaceutical forms	Oral drops
Routes of administration	Oral use

Dosage and administration details:

Placebo oral liquid once a day for two weeks.

Arm title	Levocetirizine
------------------	----------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Levocetirizine dihydrochloride
Investigational medicinal product code	LCTZ
Other name	Xyzal
Pharmaceutical forms	Oral drops
Routes of administration	Oral use

Dosage and administration details:

Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks.

Number of subjects in period 1	Placebo	Levocetirizine
Started	23	46
Completed	22	43
Not completed	1	3
Consent withdrawn by subject	1	-
Adverse event, non-fatal	-	2
SAE, non-fatal + AE, non-serious non-fatal	-	1

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: -	
Reporting group title	Levocetirizine
Reporting group description: -	

Reporting group values	Placebo	Levocetirizine	Total
Number of subjects	23	46	69
Age categorical Units: Subjects			
<=18 years	23	46	69
Age continuous Units: months arithmetic mean standard deviation	8.93 ± 1.77	8.92 ± 1.64	-
Gender categorical Units: Subjects			
Male	10	29	39
Female	13	17	30
Race Units: Subjects			
Caucasian	12	23	35
Black	9	14	23
Mixed race	2	9	11
Weight Units: lb arithmetic mean standard deviation	18.51 ± 2.73	19.55 ± 2.97	-
Height Units: inch arithmetic mean standard deviation	27.33 ± 1.67	27.97 ± 1.45	-
BMI Units: kg/m ² arithmetic mean standard deviation	17.46 ± 2.15	17.53 ± 1.75	-

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: -	
Reporting group title	Levocetirizine
Reporting group description: -	

Primary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in ventricular rate (VR)

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in ventricular rate (VR) ^[1]
End point description:	
End point type	Primary
End point timeframe:	
Baseline, 14 days	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of study A00424 was "to evaluate the safety of levocetirizine dihydrochloride in pediatric subjects aged from 6 to less than 11 months". So the purpose of the study was the description of the safety profile of levocetirizine dihydrochloride across several safety variables. Therefore no statistical comparisons were applied in this safety study.

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	38		
Units: beats per minute				
arithmetic mean (standard deviation)				
mean (SD)	-7.6 (± 17.3)	-4 (± 16.9)		

Statistical analyses

No statistical analyses for this end point

Primary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in RR interval

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in RR interval ^[2]
End point description:	
The RR interval refers to the respective time interval in the Electrocardiogram (ECG)	
End point type	Primary
End point timeframe:	
Baseline, 14 days	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of study A00424 was "to evaluate the safety of levocetirizine dihydrochloride in pediatric subjects aged from 6 to less than 11 months". So the purpose of the study was the description of the safety profile of levocetirizine dihydrochloride across several safety variables. Therefore no statistical comparisons were applied in this safety study.

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	38		
Units: milliseconds				
arithmetic mean (standard deviation)				
mean (SD)	28 (\pm 63.9)	14.9 (\pm 58.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in PR interval

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in PR interval ^[3]
-----------------	--

End point description:

The PR interval refers to the respective time interval in the Electrocardiogram (ECG)

End point type	Primary
----------------	---------

End point timeframe:

Baseline, 14 days

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of study A00424 was "to evaluate the safety of levocetirizine dihydrochloride in pediatric subjects aged from 6 to less than 11 months". So the purpose of the study was the description of the safety profile of levocetirizine dihydrochloride across several safety variables. Therefore no statistical comparisons were applied in this safety study.

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	38		
Units: milliseconds				
arithmetic mean (standard deviation)				
mean (SD)	0.8 (\pm 11.3)	3.1 (\pm 11.3)		

Statistical analyses

No statistical analyses for this end point

Primary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QRS duration

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QRS duration ^[4]
End point description: The QRS duration refers to the respective time interval in the Electrocardiogram (ECG)	
End point type	Primary
End point timeframe: Baseline, 14 days	

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of study A00424 was "to evaluate the safety of levocetirizine dihydrochloride in pediatric subjects aged from 6 to less than 11 months". So the purpose of the study was the description of the safety profile of levocetirizine dihydrochloride across several safety variables. Therefore no statistical comparisons were applied in this safety study.

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	38		
Units: milliseconds				
arithmetic mean (standard deviation)				
mean (SD)	1.4 (± 6.4)	0.3 (± 5.7)		

Statistical analyses

No statistical analyses for this end point

Primary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT interval

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT interval ^[5]
End point description: The QT interval refers to the respective time in the Electrocardiogram (ECG)	
End point type	Primary
End point timeframe: Baseline, 14 days	

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of study A00424 was "to evaluate the safety of levocetirizine dihydrochloride in pediatric subjects aged from 6 to less than 11 months". So the purpose of the study was the description of the safety profile of levocetirizine dihydrochloride across several safety variables. Therefore no statistical comparisons were applied in this safety study.

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	38		
Units: milliseconds				
arithmetic mean (standard deviation)				
mean (SD)	4.5 (± 21.1)	-0.3 (± 18.7)		

Statistical analyses

No statistical analyses for this end point

Primary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT interval corrected for heart rate using Fridericia's formula (QTcF)

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT interval corrected for heart rate using Fridericia's formula (QTcF) ^[6]
-----------------	---

End point description:

The QT interval refers to the respective time interval in the Electrocardiogram (ECG)

End point type	Primary
----------------	---------

End point timeframe:

Baseline, 14 days

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of study A00424 was "to evaluate the safety of levocetirizine dihydrochloride in pediatric subjects aged from 6 to less than 11 months". So the purpose of the study was the description of the safety profile of levocetirizine dihydrochloride across several safety variables. Therefore no statistical comparisons were applied in this safety study.

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	38		
Units: milliseconds				
arithmetic mean (standard deviation)				
mean (SD)	-1.3 (± 20.9)	-3.9 (± 17.3)		

Statistical analyses

No statistical analyses for this end point

Primary: Absolute value of QT interval corrected for heart rate using Fridericia's formula (QTcF) at Visit 3 (Day 7)

End point title	Absolute value of QT interval corrected for heart rate using Fridericia's formula (QTcF) at Visit 3 (Day 7) ^[7]
-----------------	--

End point description:

The QT interval refers to the respective time interval in the Electrocardiogram (ECG)

End point type	Primary
----------------	---------

End point timeframe:

7 days

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of study A00424 was "to evaluate the safety of levocetirizine dihydrochloride in pediatric subjects aged from 6 to less than 11 months". So the purpose of the study was the description of the safety profile of levocetirizine dihydrochloride across several safety variables. Therefore no statistical comparisons were applied in this safety study.

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21	42		
Units: milliseconds				
arithmetic mean (standard deviation)				
mean (SD)	360.3 (± 15.2)	354.5 (± 21.1)		

Statistical analyses

No statistical analyses for this end point

Primary: Absolute value of QT interval corrected for heart rate using Fridericia's formula (QTcF) at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV)

End point title	Absolute value of QT interval corrected for heart rate using Fridericia's formula (QTcF) at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) ^[8]
-----------------	---

End point description:

The QT interval refers to the respective time interval in the Electrocardiogram (ECG)

End point type	Primary
----------------	---------

End point timeframe:

14 days

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of study A00424 was "to evaluate the safety of levocetirizine dihydrochloride in pediatric subjects aged from 6 to less than 11 months". So the purpose of the study was the description of the safety profile of levocetirizine dihydrochloride across several safety variables. Therefore no statistical comparisons were applied in this safety study.

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	23	39		
Units: milliseconds				
arithmetic mean (standard deviation)				
mean (SD)	355.3 (± 17.7)	351.9 (± 18)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in total bilirubin

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in total bilirubin
End point description:	
End point type	Secondary
End point timeframe:	
Baseline, 14 days	

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	35		
Units: micromole per liter [$\mu\text{mol/L}$]				
median (full range (min-max))				
median (full range)	0 (-1.71 to 1.71)	0 (-3.42 to 3.42)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in alanine aminotransferase (ALT)

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in alanine aminotransferase (ALT)
End point description:	
End point type	Secondary
End point timeframe:	
Baseline, 14 days	

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	34		
Units: unit per liter [U/L]				
median (full range (min-max))				
median (full range)	-2 (-27 to 15)	-1 (-24 to 41)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in aspartate aminotransferase (AST)

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in aspartate aminotransferase (AST)
End point description:	
End point type	Secondary
End point timeframe:	
Baseline, 14 days	

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	34		
Units: unit per liter [U/L]				
median (full range (min-max))				
median (full range)	2 (-15 to 21)	-1 (-36 to 23)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in blood urea nitrogen

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in blood urea nitrogen
End point description:	
End point type	Secondary
End point timeframe:	
Baseline, 14 days	

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	36		
Units: millimole per liter [mmol/L]				
median (full range (min-max))				
median (full range)	0 (-0.714 to 2.856)	0 (-3.927 to 4.641)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in blood creatinine

End point title	Change from baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in blood creatinine
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, 14 days

End point values	Placebo	Levocetirizine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	36		
Units: micromole per liter [$\mu\text{mol/L}$]				
median (full range (min-max))				
median (full range)	-0.884 (-9.724 to 20.332)	-0.884 (-18.564 to 10.608)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events were collected from Visit 1 (Day -2 to -28) over randomization and On-treatment Period up to the Follow-up Visit (Day 21±2).

Adverse event reporting additional description:

Adverse Events refer to the Safety Population including all subjects who were dispensed study medication at least once.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	9.0
--------------------	-----

Reporting groups

Reporting group title	Levocetirizine
-----------------------	----------------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	Levocetirizine	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Infections and infestations			
Otitis media acute			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute sinusitis			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Levocetirizine	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 45 (64.44%)	17 / 24 (70.83%)	
Cardiac disorders			
Sinus arrhythmia			
subjects affected / exposed	1 / 45 (2.22%)	1 / 24 (4.17%)	
occurrences (all)	1	1	
Sinus bradycardia			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Somnolence			
subjects affected / exposed	2 / 45 (4.44%)	1 / 24 (4.17%)	
occurrences (all)	2	1	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	7 / 45 (15.56%)	4 / 24 (16.67%)	
occurrences (all)	7	4	
Irritability			
subjects affected / exposed	1 / 45 (2.22%)	3 / 24 (12.50%)	
occurrences (all)	1	3	
Thirst			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Injection site pain			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
Ear pruritus			
subjects affected / exposed	0 / 45 (0.00%)	1 / 24 (4.17%)	
occurrences (all)	0	1	
Eye disorders			
Eye discharge			

subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 24 (0.00%) 0	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	6 / 45 (13.33%)	1 / 24 (4.17%)	
occurrences (all)	6	1	
Teething			
subjects affected / exposed	3 / 45 (6.67%)	0 / 24 (0.00%)	
occurrences (all)	3	0	
Constipation			
subjects affected / exposed	3 / 45 (6.67%)	1 / 24 (4.17%)	
occurrences (all)	3	1	
Vomiting			
subjects affected / exposed	2 / 45 (4.44%)	1 / 24 (4.17%)	
occurrences (all)	2	1	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 45 (2.22%)	2 / 24 (8.33%)	
occurrences (all)	1	3	
Productive cough			
subjects affected / exposed	1 / 45 (2.22%)	1 / 24 (4.17%)	
occurrences (all)	1	1	
Rhinorrhoea			
subjects affected / exposed	2 / 45 (4.44%)	1 / 24 (4.17%)	
occurrences (all)	2	2	
Asthma			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Wheezing			
subjects affected / exposed	0 / 45 (0.00%)	1 / 24 (4.17%)	
occurrences (all)	0	1	
Nasal congestion			
subjects affected / exposed	0 / 45 (0.00%)	1 / 24 (4.17%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			

Dermatitis contact			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Dermatitis atopic			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Dermatitis diaper			
subjects affected / exposed	1 / 45 (2.22%)	3 / 24 (12.50%)	
occurrences (all)	1	3	
Eczema			
subjects affected / exposed	1 / 45 (2.22%)	1 / 24 (4.17%)	
occurrences (all)	1	1	
Hyperkeratosis			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Rash			
alternative dictionary used: MedDRA 9.0			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Rash papular			
subjects affected / exposed	0 / 45 (0.00%)	2 / 24 (8.33%)	
occurrences (all)	0	2	
Heat rash			
subjects affected / exposed	0 / 45 (0.00%)	1 / 24 (4.17%)	
occurrences (all)	0	1	
Pruritus			
subjects affected / exposed	0 / 45 (0.00%)	1 / 24 (4.17%)	
occurrences (all)	0	1	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Otitis media			
subjects affected / exposed	2 / 45 (4.44%)	2 / 24 (8.33%)	
occurrences (all)	2	3	

Upper respiratory tract infection subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Sinusitis subjects affected / exposed	0 / 45 (0.00%)	1 / 24 (4.17%)	
occurrences (all)	0	1	
Viral infection subjects affected / exposed	1 / 45 (2.22%)	1 / 24 (4.17%)	
occurrences (all)	1	1	
Viral upper respiratory tract infection subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Gastroenteritis subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Oral candidiasis subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Bronchitis acute subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Skin infection subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders Increased appetite subjects affected / exposed	1 / 45 (2.22%)	0 / 24 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 February 2008	A summary of the changes are as follows: <ul style="list-style-type: none">- Efficacy and serum drug concentration were included to assess compliance/drug exposure.- Risk factor information for SIDS and references were updated.- Information was included on the Population PK modeling that was used to predict the appropriate dosing regimens for children less than 6 years of age.
28 March 2008	The primary purpose of this amendment was to revise the exclusion criteria to require the specified wash-out periods for subjects who were receiving exclusionary medication via breast milk during the course of the study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

N/A

Notes: